Genetic profile of an oka varicella vaccine virus variant isolated from an infant with zoster

Journal of Clinical Microbiology

Volumn 42, Issue 12, 2004, Pages 5604-5608

  Sauerbrei, Andreas ^a   Rubtcova, Elena ^b   Wutzier, Peter ^a   Scott Schmid, D ^b   Loparev, Vladimir N ^b,c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; GENE PRODUCT; OKA VARICELLA VACCINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

AMINO ACID SUBSTITUTION; ARTICLE; DNA DETERMINATION; DNA SEQUENCE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HERPES ZOSTER; HUMAN; INFANT; NONHUMAN; NUCLEIC ACID AMPLIFICATION; OPEN READING FRAME; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VARICELLA ZOSTER VIRUS; VIRAL GENETICS; VIRUS STRAIN; WILD TYPE;

AMINO ACID SUBSTITUTION; CHICKENPOX; CHICKENPOX VACCINE; CHILD, PRESCHOOL; DNA, VIRAL; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; POLYMERASE CHAIN REACTION; VACCINATION; VARIATION (GENETICS);

DNA VIRUSES; HUMAN HERPESVIRUS 3;

EID: 10844230051     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.12.5604-5608.2004     Document Type: Article

References (27)

1. Argaw, T., J. I. Cohen, M. Klutch, K. Lekstrom, T. Yoshikawa, Y. Asano, and P. R. Krause. 2000. Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella zoster isolates. J. Infect. Dis. 181:1153-1157.
2. Arvin, A. A. 2002. Varilrix GlaxoSmithKline. Curr. Opin. Investig. Drugs 3:996-999.
3. Chen, D., E. C. Stabell, and P. D. Olivo. 1995. Varicella-zoster virus gene 51 complements a herpes simplex virus type 1 UL9 null mutant. J. Virol. 69:4515-4518.
4. Choo, P. W., J. G. Donahue, and J. E. Manson. 1995. The epidemiology of varicella and its complications. J. Infect. Dis. 172:706-712.
5. Cohen, J. I., and K. Seidel. 1994. Varicella-zoster virus (VZV) open reading frame 10 protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for VZV replication in vitro. J. Virol. 68:7850-7858.
6. Cohrs, R. J., M. Barbour, and D. H. Gilden. 1996. Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J. Virol. 70:2789-2796.
7. D'Hondt, E., E. Berge, G. Colinet, M. Duchene, and J. Peetermans. 1985. Production and quality control of the Oka-strain live varicella vaccine. Postgrad. Med. J. 61(Suppl. 4):53-56.
8. Gershon, A. A. 2001. The current status of live attenuated varicella vaccine. Arch. Virol. Suppl. 17:1-6.
9. Gomi, Y., T. Imagawa, M. Takahashi, and K. Yamanishi. 2000. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J. Med. Virol. 61:497-503.
10. Gomi, Y., T. Imagawa, M. Takahashi, and K. Yamanishi. 2001. Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental viruses. Arch. Virol. Suppl. 17:49-56.
11. Gomi, Y., H. Sunamachi, Y. Mori, K. Nagaike, M. Takahashi, and K. Yamanishi. 2002. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J. Virol. 76:11447-11459.
12. La Russa, P., O. Lungu, I. Hardy, A. Gershon, S. P. Steinberg, and S. Silverstein. 1992. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J. Virol. 66:1016-1020.
13. Levin, M. J., K. M. Dahl, A. Weinberg, R. Giller, A. Patel, and P. R. Krause. 2003. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J. Infect. Dis. 188:954-959
14. Liang, G. L., K. A. Heidelberg, R. M. Jacobson, and M. T. McEvoy. 1998. Herpes zoster after varicella vaccination. J. Am. Acad. Dermatol. 38:761-763.
15. Loparev, V. N., T. Argaw, P. R. Krause, M. Takayama, and D. S. Schmid. 2000. Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J. Clin. Microbiol. 38:3156-3160.
16. Loparev, V. N., K. McCaustland, B. P. Holloway, P. R. Krause, M. Takayama, and D. S. Schmid. 2000. Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes. J. Clin. Microbiol. 38:4315-4319.
17. Loparev, V. N., A. Gonzalez, M. Deleon-Carnes, G. Tipples, H. Fickenscher, E. G. Torfason, and D. S. Schmid. 2004. Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J. Virol. 78:8349-8358.
18. Moriuchi, M., H. Moriuchi, S. E. Straus, and J. I. Cohen. 1994. Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA. Virology 200:297-300.
19. Reddy, S. M., M. Williams, and J. I. Cohen. 1998. Expression of uracil DNA glycosylase (UNG) inhibitor in mammalian cells: varicella-zoster virus can replicate in vitro in the absence of detectable UNG activity. Virology 251:393-401.
20. Sauerbrei, A., U. Eichhorn, S. Gawellek, R. Egerer, M. Schacke, and P. Wutzler. 2003. Characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain. J. Med. Virol. 71:313-319.
21. Sauerbrei, A., B. Uebe, and P. Wutzler. 2003. Molecular diagnosis of zoster post varicella vaccination. J. Clin. Virol. 27:190-199.
22. Sauerbrei, A., and P. Wutzler. 2000. The congenital varicella syndrome. J. Perinatol. 20:548-554.
23. Sharrar, R. G., P. LaRussa, S. A. Galea, S. P. Steinberg, A. R. Sweet, R. M. Keatley, M. E. Wells, W. P. Stephenson, and A. A. Gershon. 2001. The postmarketing safety profile of varicella vaccine. Vaccine 19:916-923.
24. Ständige Impfkommission am Robert-Koch-Institut. 2001. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut/Stand: Juli 2001. Epidemiol. Bull. 28:203-218.
25. Straus, S. E., W. Reinhold, H. A. Smith, W. T. Ruyechan, D. K. Henderson, R M. Blease, and J. Hay. 1984. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N. Engl. J. Med. 311:1362-1364.
26. Takahashi, M., T. Otsuka, Y. Okuno, Y. Asano, T. Yazaki, and S. Isomura. 1974. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet ii:1288-1290.
27. Uebe, B., A. Sauerbrei, S. Burdach, and G. Horneff. 2002. Herpes zoster by reactivated vaccine varicella-zoster virus in a healthy child. Eur. J. Pediatr. 161:442-444.